SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.
Year | Receivables | Debt | Liabilities | Assets | Current Assets |
---|---|---|---|---|---|
2023 | 100.16 M | 86.65 M | 682.32 M | 2.7 B | 687.8 M |
2022 | 77.17 M | -1,317,307,915 | 224.62 M | 2.32 B | 1.79 B |
2021 | 147.97 M | -610,574,929 | 571.44 M | 2.14 B | 1.84 B |
2020 | 271.23 M | -158,746,544 | 501.86 M | 1.04 B | 918.94 M |
2019 | 19.52 M | -3,293,901 | 22.67 M | 120.97 M | 76.68 M |